Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BHST
BHST logo

BHST Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy BioHarvest Sciences Inc (BHST) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.900
1 Day change
0.35%
52 Week Range
12.800
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BHST is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The current technical setup is mixed to bearish, there is no strong proprietary buy signal, and there are no recent news or catalyst events to support an immediate entry. Since the user is impatient and does not want to wait for an optimal entry, the direct answer is still not to buy now.

Technical Analysis

Technical trend is weak. Price closed at 2.8921, slightly above the previous close, but the broader setup remains bearish with SMA_200 > SMA_20 > SMA_5, which typically indicates downward trend pressure. RSI_6 at 37.818 is neutral-to-weak and does not show strong momentum. MACD histogram is positive at 0.004 and expanding, which is mildly constructive, but it is not enough to override the bearish moving average structure. Price is also below the pivot at 3.021 and below R1 at 3.268, suggesting the stock has not reclaimed a stronger trend. Based on similar candlestick patterns, the next-day/week/month bias is negative, which further weakens the case for an immediate long-term buy.

Positive Catalysts

  • ["MACD histogram is above zero and expanding, suggesting a small momentum improvement.", "Price is close to support levels, which could attract bargain buyers if momentum improves."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst driving demand.", "No significant hedge fund or insider buying trend.", "No recent congress trading data available.", "Bearish moving average alignment: SMA_200 > SMA_20 > SMA_5.", "Probabilistic stock trend model points to weakness over the next day, week, and month.", "No AI Stock Picker signal today and no recent SwingMax signal."]

Financial Performance

No usable latest-quarter financial snapshot was provided because the financial data returned an error. As a result, there is no reliable quarter-over-quarter or year-over-year growth assessment available for the latest quarter season.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend to support a bullish case. Overall, the pros view is weak because there are no recent supportive revisions, while the cons view is stronger due to the lack of catalysts, bearish technicals, and absence of smart-money accumulation.

Wall Street analysts forecast BHST stock price to rise
3 Analyst Rating
Wall Street analysts forecast BHST stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.890
sliders
Low
12
Averages
13
High
14
Current: 2.890
sliders
Low
12
Averages
13
High
14
Roth Capital
Sean McGowan
Buy
initiated
$10
AI Analysis
2026-02-19
Reason
Roth Capital
Sean McGowan
Price Target
$10
AI Analysis
2026-02-19
initiated
Buy
Reason
Roth Capital analyst Sean McGowan initiated coverage of BioHarvest Sciences with a Buy rating and $10 price target. The firm believes the company's botanical synthesis platform will drive "significant" revenue growth in the coming years. BioHarvest's annual cash flow should turn sustainably positive beginning in 2027, the analyst tells investors in a research note. Roth cites the company's "rapid growth, expanding footprint and emerging profitability" for the Buy rating.

People Also Watch